Printer Friendly

CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER

 CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER
 WEST CHESTER, Pa., April 1 /PRNewswire/ -- Cephalon, Inc.


(NASDAQ: CEPH) announced today Dr. Shirley M. Tilghman has joined its Science Advisory Board. Dr. Tilghman is currently the Howard A. Prior Professor in the Life Sciences and an investigator of the Howard Hughes Medical Institute at Princeton University.
 Dr. Tilghman's extensive research in the control of gene expression will compliment the work currently being done at Cephalon. Dr. Frank Baldino, Jr., president and CEO of Cephalon expressed the following: "Dr. Tilghman brings new technology and genetic insight to our Science Advisory Board. This technology is extremely important to us as we move our discovery programs, including our gene expression approach to Alzheimer's disease, closer to clinical development. We are enthusiastic about the addition of Dr. Tilghman to our team."
 Dr. Tilghman is a leader in the field of molecular genetics and is credited with the cloning of the first mammalian gene. She has done seminal research regarding control mechanisms of gene regulation in animals.
 The other members making up the Science Advisory Board include Dr. Stanley Cohen, professor, Department of Biochemistry Vanderbilt University Medical Center, Nobel Prize in Medicine (1986); Dr. Stanley Appel, professor and chairman, Department of Neurology, Baylor College of Medicine; Dr. Gordon Guroff, Deputy Scientific Director, National Institute of Child Health and Human Development, National Institute of Health; Dr. Robert Moore, Director, Center for Neuroscience and Professor of Neurology and Psychiatry, University of Pittsburgh; Dr. Robert Roth, Professor, Department of Pharmacology and Psychiatry, Yale Medical School; and Dr. Philip Protoghese, Professor, Departments of Pharmacology and Psychiatry, University of Minnesota.
 Cephalon, Inc., was founded in 1987 to discover, develop and commercialize novel therapeutic products for the treatment of stroke and neurodegenerative disorders.
 -0- 4/1/92
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER


KD-KW -- NY097 -- 4076 04/01/92 17:02 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:319
Previous Article:INTERMEC PORTABLE BAR CODE READERS USED ON SPACE SHUTTLE FLIGHT
Next Article:UCI MEDICAL CENTER EXECUTIVE DIRECTOR MARY A. PICCIONE AMONG 'TEN WOMEN WHO MAKE A DIFFERENCE IN ORANGE COUNTY'
Topics:


Related Articles
CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters